Tests hesperidin supplement for fatigue and mood in multiple sclerosis
Tests a daily citrus-derived supplement against placebo in adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Hesperidin RCT in MS
Key facts
- Where
- Swansea, United KingdomSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple sclerosis. It tests whether hesperidin supplement or a placebo for 12 weeks helps fatigue, mood and thinking.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of multiple sclerosis. No stage or severity is stated.
Main reasons for not taking part
- Known food allergies or intolerances
- Significant stomach or gut (gastrointestinal) problems
- Under 18 years of age
Read by machine on 9 November 2026.
Where in United Kingdom
- FHMLS, Nutrition LabSwansea, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Swansea University
- Trial code
- NCT07452562
- Record updated
- 5 March 2026
- Original description
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress.Read full original descriptionShow less
A Randomized, Placebo-Controlled Trial of Hesperidin for Fatigue,Mood, and Cognitive Function in Multiple Sclerosis
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress.
Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
Inclusion: Diagnosis of Multiple Sclerosis, Aged 18 years or older.
Exclusion: Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.